Selling, General, and Administrative Costs: Dr. Reddy's Laboratories Limited vs PTC Therapeutics, Inc.

SG&A Expenses: A Decade of Divergence in Pharma Giants

__timestampDr. Reddy's Laboratories LimitedPTC Therapeutics, Inc.
Wednesday, January 1, 20143878300000044820000
Thursday, January 1, 20154258500000082080000
Friday, January 1, 20164570200000097130000
Sunday, January 1, 201746372000000121271000
Monday, January 1, 201846910000000153548000
Tuesday, January 1, 201948890000000202541000
Wednesday, January 1, 202050129000000245164000
Friday, January 1, 202154559000000285773000
Saturday, January 1, 202262081000000325998000
Sunday, January 1, 2023105931000000332540000
Monday, January 1, 202477201000000
Loading chart...

Unleashing insights

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing costs is as crucial as innovation. Dr. Reddy's Laboratories Limited and PTC Therapeutics, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Dr. Reddy's Laboratories saw a staggering 173% increase in SG&A expenses, peaking in 2023. This growth reflects their aggressive expansion and market penetration strategies. In contrast, PTC Therapeutics, Inc. experienced a more modest rise of approximately 643% over the same period, indicating a steady scaling of operations. Notably, Dr. Reddy's expenses in 2023 were over 300 times higher than PTC's, highlighting the vast difference in their operational scales. However, data for 2024 is incomplete, leaving room for speculation on future trends. This comparison underscores the diverse strategies companies employ to navigate the competitive pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025